Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Repligen's annualizedGross Profit for the quarter that ended in Dec. 2023 was $270.4 Mil.
Repligen's average Total Assets over the quarter that ended in Dec. 2023 was $2,669.3 Mil. Therefore, Repligen's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 10.13%.
Repligen Gross-Profit-to-Asset % Historical Data
The historical data trend for Repligen's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Repligen's Gross-Profit-to-Asset %
For the Medical Instruments & Supplies subindustry, Repligen's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Repligen's Gross-Profit-to-Asset % falls into.
Repligen Gross-Profit-to-Asset % Calculation
Repligen's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2023) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Repligen Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Repligen's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGEN has been successfully added to your 